NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Eolo Pharma

Eolo Pharma

Private
MontevideoHealthcare & Life Scienceshttps://eolo-pharma.com/

Last Round

Series A

Extension

Jul 15, 2022

Total Funding Raised

$8.4M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Eolo Pharma is a clinical-stage biotechnology company developing novel small-molecule therapies for the treatment of obesity and metabolic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydrug discoverysmall-molecule drugsobesity treatmentmetabolic diseasebiotechbrown adipose tissueclinical-stage biotechenergy expenditurepreclinical developmentGLP-1 alternativetherapeuticsdrug developmentbiopharma

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Eolo Pharma Comparables

Compare Eolo Pharma with similar companies based on industry and business-model similarity.

Eolo Pharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap

View Full Comparables Set

Access detailed peer comparisons, similarity scores, and market data.

Eolo Pharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionJul 15, 2022
Series ADec 31, 2019
Series ADec 1, 2019
SeedDec 1, 2016

Key People

Founding team and executive leadership

Carlos Batthyány

Founder CMO Eolo Pharma

Founding Team

María Pía Garat

Chief Executive Officer

Executive Team

Eolo Pharma Investors

Notable investors and investment history

Eolo Pharma investors
InvestorRounds
CITESSeries A, Series A Extension, Seed
Ficus CapitalSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 16, 2026

    Monthly visitors increased 432% MoM, reaching 2.1K.

Eolo Pharma Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Eolo Pharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Eolo Pharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersMontevideo
Employee Range17
Year Founded2017
Last FundingJul 15, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.